EMBER-3: Phase 3, Randomized, Open-Label Study Comparing LY3484356 With Investigator's Choice Hormonal Therapy in Patients With Estrogen Receptor Expressing, Locally Advanced or Metastatic Breast Cancer Without Envelope
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: LILLY, SAU
- Phase: III
- Execution start: 31/05/2021
- End of execution: 30/03/2023
- IP: ISABEL BLANCAS LOPEZ-BARAJAS